Good Health Can’t Wait, Says Dr. Reddy’s
Dr. Reddy’s launches new patient-centric branding at CPhI.
Dr. Reddy’s Laboratories is launching its new visual identity and branding rooted in the belief that “good health can’t wait” at CPhI Worldwide 2015. The purpose of the rebranding was to communicate the company’s transformation from an API manufacturer into a patient-centric multinational pharma player. Dr. Reddy’s is seeking to accelerate access to affordable and innovative medicines for people in need.
Medicines have a key role in enabling good health and improving quality of life. Dr. Reddy’s new branding and heart logo reflect this belief and reinforce the company’s pledge to provide tomorrow’s healthcare solutions today.
Dr. Reddy’s Active Ingredients and Custom Pharma Services (CPS) arms support global pharma companies in their quest to accelerate delivery of medicinal therapies. CPS offers manufacturing services and solutions for starting materials, intermediates, active ingredients, and finished dosage form. Partners have access to the company’s expertise and technologies (e.g., peptides, chirals, HPAPIs, steroids, activated mPEGs) as well as a global delivery network and intermediate and API portfolio.
Source: Dr. Reddy’s, Booth 6D30
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
